Tuvirumab
Tuvirumab
Tuvirumab (pronounced: too-vee-roo-mab) is a monoclonal antibody designed for the treatment of various types of cancer. It is a type of biological therapy that targets specific proteins on cancer cells to inhibit their growth and spread.
Etymology
The name "Tuvirumab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the prefix "Tuviru-" does not have a specific meaning and is used for distinction.
Mechanism of Action
Tuvirumab works by binding to specific proteins on the surface of cancer cells. This binding action can block the signals that tell the cancer cells to grow and divide, effectively slowing or stopping the progression of the disease. The specific proteins that Tuvirumab targets depend on the type of cancer it is used to treat.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Biological therapy: Treatment to stimulate or restore the ability of the immune system to fight cancer, infections, and other diseases.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
See Also
External links
- Medical encyclopedia article on Tuvirumab
- Wikipedia's article - Tuvirumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski